The prevalence and antifolate drug resistance profiles of Plasmodium falciparum in study participants randomized to discontinue or continue cotrimoxazole prophylaxis.

The prevalence and antifolate drug resistance profiles of Plasmodium falciparum in study participants randomized to discontinue or continue cotrimoxazole prophylaxis.

OBJECTIVE:Cotrimoxazole prevents opportunistic infections including falciparum malaria in HIV-infected individuals but there are concerns of cross-resistance to other antifolate drugs such as sulphadoxine-pyrimethamine (SP). In this study, we investigated the prevalence of antifolate-resistance muta...

Full description

Bibliographic Details
Main Authors:	Dennis W Juma, Peninah Muiruri, Krista Yuhas, Grace John-Stewart, Ronald Ottichilo, John Waitumbi, Benson Singa, Christina Polyak, Edwin Kamau
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2019-03-01
Series:	PLoS Neglected Tropical Diseases
Online Access:	http://europepmc.org/articles/PMC6445470?pdf=render

Similar Items

Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial.
by: Christina S Polyak, et al.
Published: (2016-01-01)

Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan.
by: Awab, G, et al.
Published: (2013)

Independent Origin of Plasmodium falciparum Antifolate Super-Resistance, Uganda, Tanzania, and Ethiopia
by: Michael Alifrangis, et al.
Published: (2014-08-01)

Submicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western Kenya.
by: Mayke J A M Oesterholt, et al.
Published: (2009-01-01)

Tracing the origins and signatures of selection of antifolate resistance in island populations of <it>Plasmodium falciparum</it>
by: Pinto João, et al.
Published: (2010-06-01)

Escalating <it>Plasmodium falciparum </it>antifolate drug resistance mutations in Macha, rural Zambia
by: Rouse Petrica, et al.
Published: (2008-05-01)

Molecular markers of antifolate resistance in <it>Plasmodium falciparum </it>isolates from Luanda, Angola
by: Almeida de Oliveira Natália K, et al.
Published: (2011-08-01)

Rapid genotyping of loci involved in antifolate drug resistance in Plasmodium falciparum by primer extension.
by: Nair, S, et al.
Published: (2002)

Molecular correlates of high-level antifolate resistance in Rwandan children with Plasmodium falciparum malaria.
by: Karema, C, et al.
Published: (2010)

Molecular characterization of Plasmodium falciparum antifolate resistance markers in Thailand between 2008 and 2016
by: Sugaram, R, et al.
Published: (2020)

Molecular characterization of Plasmodium falciparum antifolate resistance markers in Thailand between 2008 and 2016
by: Rungniran Sugaram, et al.
Published: (2020-03-01)

Type 2 antifolates in the chemotherapy of falciparum malaria
by: Delfino Reinaldo T., et al.
Published: (2002-01-01)

Cotrimoxazole prophylaxis for infants exposed to HIV infection
by: Stephen M. Graham

Cotrimoxazole prophylaxis for infants exposed to HIV infection
by: Stephen M. Graham
Published: (2004-04-01)

A genetically hard-wired metabolic transcriptome in Plasmodium falciparum fails to mount protective responses to lethal antifolates.
by: Karthikeyan Ganesan, et al.
Published: (2008-11-01)

Genetically Determined Response to Artemisinin Treatment in Western Kenyan Plasmodium falciparum Parasites.
by: Lorna J Chebon, et al.
Published: (2016-01-01)

Increased malaria parasitaemia among adults living with HIV who have discontinued cotrimoxazole prophylaxis in Kitgum district, Uganda.
by: Philip Orishaba, et al.
Published: (2020-01-01)

Effects of antifolates - co-trimoxazole and pyrimethamine-sulfadoxine - on gametocytes in children with acute, symptomatic, uncomplicated, Plasmodium falciparum malaria
by: A Sowunmi, et al.
Published: (2005-07-01)

Apoptosis stalks <it>Plasmodium falciparum</it> maintained in continuous culture condition
by: Waitumbi John N, et al.
Published: (2010-12-01)

The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.
by: Ryan, M, et al.
Published: (2008)

Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China
by: Wei Cheng, et al.

Reconsidering empirical cotrimoxazole prophylaxis for infants exposed to HIV infection
by: Gill Christopher J., et al.
Published: (2004-01-01)

Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV.
by: Christopher J Hoffmann, et al.
Published: (2014-01-01)

Temporal trends in prevalence of Plasmodium falciparum molecular markers selected for by artemether–lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya
by: Angela O. Achieng, et al.
Published: (2015-12-01)

Complement activation by merozoite antigens of Plasmodium falciparum.
by: Jackson C Korir, et al.
Published: (2014-01-01)

Eligibility for cotrimoxazole prophylaxis among adult HIVinfected patients in South Africa
by: S Takuva, et al.
Published: (2019-04-01)

Complement consumption in children with <it>Plasmodium falciparum </it>malaria
by: Makumi Joseph N, et al.
Published: (2009-01-01)

Ten-year persistence and evolution of Plasmodium falciparum antifolate and anti-sulfonamide resistance markers pfdhfr and pfdhps in three Asian countries
by: Srisutham, S, et al.
Published: (2022)

Ten-year persistence and evolution of Plasmodium falciparum antifolate and anti-sulfonamide resistance markers pfdhfr and pfdhps in three Asian countries.
by: Suttipat Srisutham, et al.
Published: (2022-01-01)

The Impact of Short-Term, Intensive Antifolate Treatment (with Pyrimethamine and Sulfadoxine) and Antibiotics Followed by Long-Term, Secondary Antifolate Prophylaxis on the Rate of Toxoplasmic Retinochoroiditis Recurrence.
by: Piotr K Borkowski, et al.
Published: (2016-08-01)

National policy development for cotrimoxazole prophylaxis in Malawi, Uganda and Zambia: the relationship between Context, Evidence and Links
by: Chishinga Nathaniel, et al.
Published: (2011-06-01)

Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax.
by: Leartsakulpanich, U, et al.
Published: (2002)

Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis.
by: Prendergast, A, et al.
Published: (2011)

Time for new recommendations on cotrimoxazole prophylaxis for HIV-exposed infants in developing countries?
by: Anna Coutsoudis, et al.
Published: (2010-12-01)

Time for new recommendations on cotrimoxazole prophylaxis for HIV-exposed infants in developing countries?
by: Anna Coutsoudis, et al.

Factors associated with coverage of cotrimoxazole prophylaxis in HIV-exposed children in South Africa.
by: Dhayendre Moodley, et al.
Published: (2013-01-01)

Linking HIV-infected TB patients to cotrimoxazole prophylaxis and antiretroviral treatment in India.
by: Neeraj Raizada, et al.
Published: (2009-06-01)

Polymorphisms in Plasmodium vivax antifolate resistance markers in Afghanistan between 2007 and 2017
by: Rakmark, K, et al.
Published: (2020)

Polymorphisms in Plasmodium vivax antifolate resistance markers in Afghanistan between 2007 and 2017
by: Kasama Rakmark, et al.
Published: (2020-07-01)

Some aspects of treatment, prophylaxis and chemoresistance of plasmodium falciparum malaria
by: Marcos Boulos, et al.
Published: (1986-01-01)